LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.

Core Insights - Exousia Bio, Inc. has completed the acquisition of Exousia AI, Inc. in an all-stock transaction, issuing 62,223,000 restricted shares to consolidate ownership of a promising preclinical oncology platform [1] - The acquisition strengthens Exousia Bio's position in the exosome technology space, with two exclusive worldwide licenses secured for critical areas in cancer therapy and targeted drug delivery [2] - The company has received Orphan Drug Designation (ODD) from the FDA for its Glioblastoma therapy, marking a significant regulatory milestone [3][4] Financial and Strategic Advantages - The ODD provides substantial financial and strategic benefits, including an estimated potential value in the tens of millions of dollars [6] - The designation guarantees seven years of market exclusivity post-approval, offering a competitive advantage and protecting future revenue streams [10] - The company will benefit from tax credits for qualified clinical research costs and a waiver of New Drug Application user fees [10] Research and Development Progress - A completed in-vivo mouse study has shown extremely positive results for using exosomes to treat Glioblastoma multiforme, with findings being prepared for peer-reviewed publication [7] - To support the advancement of its pipeline, the company plans to expand its executive leadership and Board of Directors, including the appointment of a Chief Science Officer and Chief Medical Officer [8] Company Overview - Exousia Bio, Inc. specializes in developing and manufacturing mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery [9] - The platform aims to address significant unmet medical needs, particularly in targeting cancer stem cells and treating a broad spectrum of viral infections [11]